Free Trial

Galapagos (GLPG) Competitors

Galapagos logo
$32.65 +1.80 (+5.83%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$32.65 0.00 (-0.02%)
As of 07/25/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GLPG vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, AMPE, ACABW, BFRIW, BTMDW, and BCTXW

Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Ampio Pharmaceuticals (AMPE), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), and BriaCell Therapeutics (BCTXW). These companies are all part of the "pharmaceutical products" industry.

Galapagos vs. Its Competitors

180 Life Sciences (NASDAQ:ATNFW) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

32.5% of Galapagos shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Galapagos had 5 more articles in the media than 180 Life Sciences. MarketBeat recorded 6 mentions for Galapagos and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat Galapagos' score of 0.43 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
Galapagos Neutral

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Galapagos N/A N/A N/A

Galapagos has higher revenue and earnings than 180 Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Galapagos$298.31MN/A$80.16MN/AN/A

Galapagos has a consensus price target of $25.33, indicating a potential downside of 22.41%. Given Galapagos' stronger consensus rating and higher possible upside, analysts clearly believe Galapagos is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Galapagos
4 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Galapagos beats 180 Life Sciences on 6 of the 7 factors compared between the two stocks.

Get Galapagos News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLPG vs. The Competition

MetricGalapagosMED IndustryMedical SectorNASDAQ Exchange
Market CapN/A$3.05B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.2320.08
Price / SalesN/A282.17430.5089.23
Price / Cash42.4942.7636.2258.56
Price / Book0.698.378.665.88
Net Income$80.16M-$55.19M$3.25B$258.72M
7 Day Performance4.85%5.86%4.24%3.72%
1 Month Performance16.32%17.29%10.51%11.73%
1 Year Performance18.81%4.39%34.43%18.02%

Galapagos Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLPG
Galapagos
0.4521 of 5 stars
$32.65
+5.8%
$25.33
-22.4%
+19.2%$0.00$298.31M0.001,310Analyst Upgrade
Analyst Revision
ATNFW
180 Life Sciences
N/A$0.01
-1.2%
N/A+22.2%$0.00N/A0.007Positive News
Gap Down
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522K0.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.00
-63.4%
N/AN/A$0.00N/A0.002
AIMDW
Ainos
N/A$0.12
+2.2%
N/A+95.0%$0.00$106.21K0.0040Positive News
Gap Down
ALVOW
Alvotech
N/A$1.65
-7.3%
N/A-0.7%$0.00$585.60M0.004Positive News
Gap Down
AMPE
Ampio Pharmaceuticals
N/AN/AN/A+154.5%$0.00N/A0.0020Gap Down
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.04
+75.5%
N/AN/A$0.00N/A0.0015
BFRIW
Biofrontera
N/A$0.11
+21.5%
N/AN/A$0.00$38.00M0.0070Positive News
Gap Up
BTMDW
biote
N/A$0.01
-3.4%
N/A-96.8%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.05
-29.9%
N/A-78.1%$0.00N/A0.008Positive News
Gap Down

Related Companies and Tools


This page (NASDAQ:GLPG) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners